The field of stereotactic radiosurgery (SRS) was established by Lars Leksell in the 1950s as an adjunct to treatment of deep brain lesions otherwise not accessible to more conventional neurosurgery. Initially the focus of SRS was generation of functional lesions. Over time the procedure evolved and its focus expanded so that SRS now includes treatment of benign neoplastic or vascular lesions such as arteriovenous malformations (AVMs), meningiomas, and vestibular schwannomas. Since the mid1990s, SRS has achieved a prominent role in the management of both brain and spinal benign and malignant tumors.
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When the focus of neurosurgical intervention was single benign lesions, the neurosurgeon was the primary decision maker in offering SRS as part of an armamentarium of lesion management options. Proper application of the stereotactic head frame and a sound understanding of the anatomical and physiological implications of adjacent brain areas were paramount in ensuring delivery of high-quality ongoing care for these patients.
Before the development of radiosurgical technologies that facilitate treatment of multiple tumors in 1 to 5 SRS sessions, most patients with metastatic brain cancer received whole brain radiation therapy as their only treatment option. Today treatment of brain and spine metastases is the most common indication for SRS. With this dramatic shift in the focus of SRS, the relative roles of the radiation oncologist, medical physicist, and neurosurgeon now vary considerably. Current spine and body radiosurgical procedures require increasingly complex linear accelerator (LINAC)-based technologies that are not included in the training of most neurological surgeons. Neurosurgical training includes acquisition of critical knowledge of neurological anatomy and function as well as alternative neurosurgical options and their outcomes. To date, radiosurgical treatment has achieved widespread implementation because of careful patient selection, optimal treatment planning, and dose delivery based on direct participation by a trained and responsible neurosurgeon partnering with a trained radiation oncologist. Loss of neurosurgery leadership in this process puts the radiosurgery field and, potentially, patients at risk.
According to data obtained from Elekta AB, the manufacturer of Gamma Knife SRS technology, more than 700,000 patients underwent brain SRS worldwide during the last 33 years. The total number of LINAC SRS procedures remains unknown. The market research firm IMV estimates that 32,335 patients in the US underwent cranial LINAC SRS or Gamma Knife surgery (GKS) in 2009 and that the average increase in patient volume is 10% per year. The Center for Medicare and Medicaid Services reports that in 2010 the primary GKS hospital billing code, 77371, was billed 5,929 times, and the primary LINAC SRS billing code, G0339, was billed 9,337 times. The staged LINAC SRS billing code, G0340 (which represents image-guided robotic LINAC-based SRS, second through fifth sessions), was billed 22,193 times in the same year. Elekta, the Gamma Knife manufacturer, notes that 15,000 patients in the US underwent GKS in 2011. Despite this, current US neurosurgery residents participate in the delivery of less than 5% of radiosurgical procedures, even though most US teaching hospitals with more than 400 beds have SRS technologies.
In March 2012, we asked Katie O. Orrico, J.D., of the American Association of Neurological SurgeonsCongress of Neurological Surgeons (AANS-CNS) Washington Committee to review the number of SRS Current Procedural Terminology (CPT) codes submitted for payment to the Center for Medicaid and Medicare Services between 1993 and 2011 and to compare these numbers to the number of CPT codes submitted for craniotomy for tumor, not meningioma within the same interval. The data she provided are shown in Fig. 1 upper. In 2003 the number of CPT codes for radiosurgery (then 61793) that were submitted exceeded the number of codes submitted for craniotomy for tumor, not meningioma (Fig. 1 lower) .
There are currently no clear program requirements for the training of neurosurgical residents in SRS. Relatively few programs offer dedicated "hands-on" experiEditorial ence in SRS. While there are no "mandated" number of SRS cases, SRS experience in neurosurgery programs can be tracked using the Accreditation Council for Graduate Medical Education (ACGME) Accreditation Data System software that residents use to report their neurosurgery case loads. The US national resident experience in radiosurgery in 2011 included an average of 3 AVMs, 25 tumors, 5 functional neurosurgery cases, 3 spine cases, and 1 pediatric SRS case. The ACGME's Residency Review Committee for Neurosurgery recently defined the minimum numbers of cases required for residents in training as 10 SRS cases and 60 craniotomies for tumors during the 7-year neurosurgery residency.
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Current requirements in radiation oncology training (effective January 2009, as cited in the ACGME radiation oncology program requirements PV IV.A. 5a) include a minimum experience of 10 intracranial cases and 5 spine and body cases during residency. It is therefore conceivable that teams of untrained neurosurgeons and radiation oncologists could be partnering to perform SRS procedures based on a minimal knowledge of the indications, methodologies, and potential risks of the procedure.
For the field of neurosurgery to remain an equal partner in the provision of SRS care, it is necessary that we provide adequate SRS training to our residents. Decreasing third party reimbursement of neurosurgeons, despite ongoing active participation in SRS, seems to reflect a public view that neurosurgical input into treatment delivery is of diminishing importance. As neurosurgeons, however, we must recognize that loss of neurosurgical input into SRS procedures will absolutely compromise the quality of ongoing care of the patient's neurological condition. It will also further distance our specialty from multidisciplinary care of patients with cancer.
As with all areas of neurosurgical training, experience in the use of SRS allows the resident to learn the advantages and limitations of various SRS technologies. While training does not need to be so comprehensive as to reach the level of expert user, neurosurgery residents need to be aware of the current indications, outcomes, and risks of SRS. Residents also need sufficient understanding of the procedure to provide adequate patient education about risks, benefits, and anticipated outcomes for particular clinical problems. Last, to continue to participate as coequal partners in the multidisciplinary SRS team, neurosurgeons need an adequate knowledge base to practice safe and effective SRS for diseases of the central nervous system.
The disease processes for which SRS is being routinely used in the US include the following:
1. AVMs 2. meningiomas 3. vestibular schwannomas 4. trigeminal neuralgia 5. pituitary adenomas 6. single and multiple metastases from cancer of the lung, breast, colon, kidney, ovary, prostate, and melanoma 7. recurrent ependymomas 8. selected glial neoplasms 9. miscellaneous skull-base tumors 10. paraspinal and spinal metastases 11. benign tumors of the spine such as schwannomas and chordomas 12. functional indications (epilepsy and movement and behavioral disorders)
The technologies that are available to deliver SRS include:
1. Leksell Gamma Knife® (Elekta AB) 2. LINAC-based technologies including but not limited to the Cyberknife® (Accurray Inc.), Synergy® (Elekta AB), Trilogy® and TrueBeam™ (Varian Medical System), XKnife® (Integra LifeSciences Corp.), and Novalis® (Brainlab) 3. proton beam therapy It is important therefore for the neurosurgical resident to learn the following:
1. criteria for the safe use of SRS in each of the aforementioned diagnoses 
